论文部分内容阅读
目的:观察盐酸吡格列酮片治疗初发2型糖尿病的临床疗效及安全性。方法:选择双盲、随机、安慰剂对照的方法,实验组给予盐酸吡格列酮30mg治疗,对照组给予安慰剂治疗,每日1次,观察时间为3个月。结果:实验组盐酸吡格列酮降低空腹血糖的显效率、有效率为35.3%、79.4%,降低餐后2h血糖的显效率和有效率分别为38.2%和85.3%,安慰剂和吡格列酮的差异具有统计学意义(P<0.01)。结论:盐酸吡格列酮是初发2型糖尿病患者一种理想的治疗药物。
Objective: To observe the clinical efficacy and safety of pioglitazone hydrochloride tablets in the treatment of newly diagnosed type 2 diabetes mellitus. Methods: A double-blind, randomized, placebo-controlled trial was conducted. The experimental group was given pioglitazone hydrochloride 30 mg and the control group was given placebo. The observation time was 3 months. Results: In the experimental group, pioglitazone hydrochloride reduced the effective rate of fasting blood glucose, the effective rates were 35.3% and 79.4%, and the effective and effective rates of reducing blood glucose 2h after meal were 38.2% and 85.3% respectively. The difference between placebo and pioglitazone was statistically significant Significance (P <0.01). Conclusion: Pioglitazone hydrochloride is an ideal treatment for newly diagnosed type 2 diabetic patients.